Journal Article
. 2013 Mar;8(3).
doi: 10.1371/journal.pone.0058483.

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer

Zsuzsanna Varga 1 Peter Sinn  Florian Fritzsche  Arthur von Hochstetter  Aurelia Noske  Peter Schraml  Christoph Tausch  Andreas Trojan  Holger Moch  
Affiliations
  • PMID: 23505515
  •     41 References
  •     25 citations

Abstract

Aim: Several multigene expression-based tests offering prognostic and predictive information in hormone-receptor positive early breast cancer were established during the last years. These tests provide prognostic information on distant recurrences and can serve as an aid in therapy decisions. We analyzed the recently validated reverse-transcription-quantitative-real-time PCR-based multigene-expression Endopredict (EP)-test on 34 hormone-receptor positive breast-cancer cases and compared the EP scores with the Oncotype DX Recurrence-scores (RS) obtained from the same cancer samples.

Methods: Formalin-fixed, paraffin-embedded invasive breast-cancer tissues from 34 patients were analyzed by the EP-test. Representative tumor blocks were analyzed with Oncotype DX prior to this study. Tumor tissue was removed from unstained slides, total-RNA was isolated and EP-analysis was performed blinded to Oncotype DX results.

Results: Extraction of sufficient amounts of RNA and generation of valid EP-scores were possible for all 34 samples. EP classified 11 patients as low-risk and 23 patients as high-risk. RS Score defined 15 patients as low-risk, 10 patients as intermediate-risk in and 9 patients as high-risk. Major-discrepancy occurred in 6 of 34 cases (18%): Low-risk RS was classified as high-risk by EP in 6 cases. Combining the RS intermediate-risk and high-risk groups to a common group, the concordance between both tests was 76%. Correlation between continuous EP and RS-scores was moderate (Pearson-coefficient: 0.65 (p<0.01).

Conclusion: We observed a significant but moderate concordance (76%) and moderate correlation (0.65) between RS and EP Score. Differences in results can be explained by different weighting of biological motives covered by the two tests. Further studies are needed to explore the clinical relevance of discrepant test results with respect of outcome.

How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.
Zsuzsanna Varga, Joachim Diebold, +16 authors, Hans-Anton Lehr.
PLoS One, 2012 Jun 05; 7(5). PMID: 22662150    Free PMC article.
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Catherine M Kelly, Philip S Bernard, +7 authors, Lajos Pusztai.
Oncologist, 2012 Mar 16; 17(4). PMID: 22418568    Free PMC article.
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, +9 authors, C Swanton.
Ann Oncol, 2013 Jan 23; 24(3). PMID: 23337633    Free PMC article.
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
B Weigelt, J S Reis-Filho, C Swanton.
Ann Oncol, 2012 Sep 26; 23 Suppl 10. PMID: 22987965
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.
Zsuzsanna Varga, Rosmarie Caduff, Bernhard Pestalozzi.
Virchows Arch, 2005 Jan 15; 446(2). PMID: 15650840
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Molecular profiling in breast cancer.
Shannon R Morris, Lisa A Carey.
Rev Endocr Metab Disord, 2007 Apr 28; 8(3). PMID: 17464566
Review.
Systematic review: gene expression profiling assays in early-stage breast cancer.
Luigi Marchionni, Renee F Wilson, +4 authors, Steven N Goodman.
Ann Intern Med, 2008 Feb 07; 148(5). PMID: 18252678
Systematic Review.
Commercialized multigene predictors of clinical outcome for breast cancer.
Jeffrey S Ross, Christos Hatzis, +2 authors, Gabriel N Hortobágyi.
Oncologist, 2008 Jun 03; 13(5). PMID: 18515733
Review.
Histopathologic variables predict Oncotype DX recurrence score.
Melina B Flanagan, David J Dabbs, +2 authors, Rohit Bhargava.
Mod Pathol, 2008 Mar 25; 21(10). PMID: 18360352
Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
Jessica A Rayhanabad, L Andrew Difronzo, Phillip I Haigh, Lina Romero.
Am Surg, 2008 Oct 24; 74(10). PMID: 18942607
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.
Catherine Oakman, Silvia Bessi, +3 authors, Angelo Di Leo.
Breast Cancer Res, 2009 May 14; 11(2). PMID: 19435470    Free PMC article.
Review.
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Jeffrey S Ross.
Adv Anat Pathol, 2009 Jun 24; 16(4). PMID: 19546609
Review.
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Kathy S Albain, Soonmyung Paik, Laura van't Veer.
Breast, 2009 Nov 17; 18 Suppl 3. PMID: 19914534
Review.
Women's experiences with genomic testing for breast cancer recurrence risk.
Janice P Tzeng, Deborah Mayer, +5 authors, Noel T Brewer.
Cancer, 2010 Mar 10; 116(8). PMID: 20213682
Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.
Kyoko Yorozuya, Toru Takeuchi, +9 authors, Shogo Kikuchi.
J Cancer Res Clin Oncol, 2009 Dec 01; 136(6). PMID: 19946706
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Siobhan M O'Connor, Sushil Beriwal, David J Dabbs, Rohit Bhargava.
Appl Immunohistochem Mol Morphol, 2010 Feb 27; 18(3). PMID: 20186046
Gene expression profiling in breast cancer.
Kiran Turaga, Geza Acs, Christine Laronga.
Cancer Control, 2010 Jul 29; 17(3). PMID: 20664515
Review.
The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
Joseph Geradts, Sarah M Bean, Rex C Bentley, William T Barry.
Cancer Invest, 2010 Sep 30; 28(9). PMID: 20873988
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Catherine M Kelly, Savitri Krishnamurthy, +4 authors, Lajos Pusztai.
Cancer, 2010 Jul 29; 116(22). PMID: 20665886
Knowledge of genomic testing among early-stage breast cancer patients.
Alice R Richman, Janice P Tzeng, +2 authors, Noel T Brewer.
Psychooncology, 2010 Mar 05; 20(1). PMID: 20200857
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
Berit Maria Müller, Ralf Kronenwett, +11 authors, Carsten Denkert.
Diagn Mol Pathol, 2011 Feb 18; 20(1). PMID: 21326033
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Personalized medicine: the road ahead.
Rutika Mehta, Rohit K Jain, Sunil Badve.
Clin Breast Cancer, 2011 Mar 23; 11(1). PMID: 21421518
Review.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Daron J Williams, Cynthia Cohen, +3 authors, Amy L Adams.
Appl Immunohistochem Mol Morphol, 2011 Feb 08; 19(5). PMID: 21297447
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Is gene array testing to be considered routine now?
Soonmyung Paik.
Breast, 2011 Nov 02; 20 Suppl 3. PMID: 22015300
Review.
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
Arif H Kamal, Charles L Loprinzi, +7 authors, Matthew P Goetz.
Oncologist, 2011 Sep 22; 16(10). PMID: 21934103    Free PMC article.
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
S Sahebjam, R Aloyz, +6 authors, L C Panasci.
Br J Cancer, 2011 Oct 06; 105(9). PMID: 21970880    Free PMC article.
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
David J Dabbs, Molly E Klein, +3 authors, Rohit Bhargava.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990395
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Knowledge about genomic recurrence risk testing among breast cancer survivors.
Isaac M Lipkus, Susan T Vadaparampil, Paul B Jacobsen, Cheryl A Miree.
J Cancer Educ, 2011 Jun 21; 26(4). PMID: 21688183
Prognostic or predictive? It's time to get back to definitions!
Antoine Italiano.
J Clin Oncol, 2011 Nov 02; 29(35). PMID: 22042948
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
J Albanell, A González, +17 authors, A Lluch.
Ann Oncol, 2011 Jun 10; 23(3). PMID: 21652577
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Carsten Denkert, Ralf Kronenwett, +23 authors, Manfred Dietel.
Virchows Arch, 2012 Mar 01; 460(3). PMID: 22371223    Free PMC article.
Clinical advances in molecular biomarkers for cancer diagnosis and therapy.
Seema Sethi, Shadan Ali, Philip A Philip, Fazlul H Sarkar.
Int J Mol Sci, 2013 Jul 19; 14(7). PMID: 23863689    Free PMC article.
Review.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
Nicholas P Tobin, Linda S Lindström, +3 authors, Kristian Wennmalm.
Mol Oncol, 2014 Mar 19; 8(3). PMID: 24630985    Free PMC article.
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
P Sinn, S Aulmann, +6 authors, A Schneeweiss.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(9). PMID: 24771945    Free PMC article.
How does genome sequencing impact surgery?
Marlies S Reimers, Charla C Engels, +2 authors, Gerrit J Liefers.
Nat Rev Clin Oncol, 2014 Jun 25; 11(10). PMID: 24958181
Review.
[Molecular pathology for breast cancer: Importance of the gene expression profile].
C Denkert, B M Pfitzner, B I Heppner, M Dietel.
Pathologe, 2015 Apr 04; 36(2). PMID: 25836324
Review.
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.
Zsuzsanna Varga, Estelle Cassoly, +6 authors, Thomas Ruhstaller.
PLoS One, 2015 Apr 18; 10(4). PMID: 25885288    Free PMC article.
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Michael D Alvarado, Che Prasad, +5 authors, Christos J Markopoulos.
Adv Ther, 2015 Nov 28; 32(12). PMID: 26610383    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
Andreas Bösl, Andreas Spitzmüller, +3 authors, Felix Offner.
PLoS One, 2017 Aug 30; 12(8). PMID: 28850621    Free PMC article.
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
Johannes Ettl, Evelyn Klein, +7 authors, Marion Kiechle.
PLoS One, 2017 Sep 07; 12(9). PMID: 28877230    Free PMC article.
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
Alberto Peláez-García, Laura Yébenes, +9 authors, David Hardisson.
PLoS One, 2017 Sep 09; 12(9). PMID: 28886093    Free PMC article.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients.
Tzu-Ting Huang, Nicolas Pennarun, +3 authors, Skye Hung-Chun Cheng.
Oncotarget, 2018 May 26; 9(33). PMID: 29796180    Free PMC article.
Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
Yun Yeong Kim, Se Jeong Oh, +2 authors, Heung Kyu Park.
PLoS One, 2018 Jul 07; 13(7). PMID: 29979736    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Hatem Soliman, Susanne Wagner, +9 authors, William Gradishar.
Ann Surg Oncol, 2020 Jan 08; 27(3). PMID: 31907749    Free PMC article.
Indications for prognostic gene expression profiling in early breast cancer.
Erin F Cobain, Daniel F Hayes.
Curr Treat Options Oncol, 2015 May 02; 16(5). PMID: 25929335
Review.
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
Aurelia Noske, Sophie-Isabelle Anders, +6 authors, Evelyn Klein.
Breast, 2019 Dec 02; 49. PMID: 31786414    Free PMC article.
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Tomás Pascual, Miguel Martin, +21 authors, Aleix Prat.
Front Oncol, 2019 May 21; 9. PMID: 31106144    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Aditya K Sengupta, Aparna Gunda, +4 authors, Manjiri M Bakre.
Cancer Med, 2020 Oct 08; 9(21). PMID: 33027559    Free PMC article.
Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.
Jeeyeon Lee, Eun Hye Lee, +9 authors, Jin Hyang Jung.
BMC Cancer, 2019 Apr 27; 19(1). PMID: 31023265    Free PMC article.
Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Mariana Bustamante Eduardo, Vlad Popovici, +5 authors, Rolf Jaggi.
BMC Cancer, 2019 Jun 09; 19(1). PMID: 31174485    Free PMC article.